Xconomy Boston

BioVex Garners $30,000,000 Series F Funding

  • Feed Type
  • Date
    11/10/2009
  • Company Name
    BioVex
  • Mailing Address
    34 Commerce Way Woburn, MA 01801
  • Company Description
    The Company is developing a new class of potent biologics for the treatment
    of cancer and prevention of infectious disease.
  • Website
    http://www.biovex.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series F
  • Proceeds Purposes
    The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
  • M&A Terms
  • Venture Investor
    Morningside Group
  • Venture Investor
    Ventech
  • Venture Investor
    MVM Life Science Partners
  • Venture Investor
    Undisclosed

Related Topics

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.